SCHEMBL2180443

SCHEMBL2180443

CNc1nccc(-c2cc(NC(=O)CN3CCN(c4ccccn4)CC3)c3cc(OC)ccc3c2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
KDM4E B2RXH2 2/20 0.54
HPGD P15428 2/20 0.54
HIF1A Q16665 1/20 0.54
KMT2A Q03164 5/20 0.53
MEN1 O00255 4/20 0.53
MAPT P10636 6/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
TSHR P16473 4/20 0.51
LMNA P02545 3/20 0.51
GAA P10253 1/20 0.48
POLB P06746 1/20 0.48
USP2 O75604 2/20 0.48
HSD17B10 Q99714 1/20 0.48
THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2180337 0.90 KDM4E (0.43) ALDH1A1SMN1; SMN2KDM4EHPGDHIF1A
SCHEMBL2178170 0.88 KMT2A (0.43) ALDH1A1SMN1; SMN2KDM4EHPGDHIF1A
SCHEMBL2179634 0.88 TSHR (0.46) ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1
SCHEMBL12487126 0.87 KDR (0.41) ALDH1A1SMN1; SMN2KDM4EHPGDHIF1A
SCHEMBL2178631 0.87 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2KDM4EHPGDHIF1A
SCHEMBL2179413 0.87 MAPT (0.41) ALDH1A1SMN1; SMN2KDM4EHPGDHIF1A
SCHEMBL2178573 0.87 TP53 (0.45) ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1
SCHEMBL2184977 0.87 KDR (0.42) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL2180704 0.86 ATM (0.46) ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1
SCHEMBL2179087 0.86 KMT2A (0.42) ALDH1A1SMN1; SMN2KDM4EHPGDHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US claimed
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US disclosed
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US disclosed
WO-2011082268-A2 SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS ARQULE INC. (US) 2011-07-07 WO disclosed
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds ARQULE, INC. (US) 2011-07-07 US disclosed
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds ARQULE, INC. (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds DPYD, TP53, TYMP ALDH1A1 619/4885SMN1; SMN2 1358/4885KDM4E 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.